Background: Antidepressant use is highly prevalent. Research has mainly focused on efficacy during short periods of use for depression and anxiety. There is a relative paucity of data regarding the frequency of long-term use. Methods: To determine the prevalence and possible increase of long-term use of antidepressants over recent years, we analyzed routine general practice care data in a large cohort of patients (n = 156,620) in and around Amsterdam, The Netherlands. Additionally, predictors of long-term use were studied. Results: Prevalence of long-term use of antidepressants is substantial, and such use appears to be increasing: 30.3% of use was long-term over the period 1995-2005 compared to 43.7% for the period 2005-2015. Higher age, a registered diagnosis of anxiety or depression, and the use of SSRIs or SNRIs were associated with long-term use in multivariate analysis. In addition, specific antidepressants were differentially associated with long-term use. Conclusions: Long-term antidepressant use is substantial and appears to be on the rise. Awareness of this phenomenon should be increased, such use should be prevented when possible, and reasons for long-term use need to be examined.

Keywords:
Depressive disorder, Anxiety, Antidepressant medication, Disease management, Long-term care
1.
Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 2007;8:67-104.
2.
Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P, et al: Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol (Oxf) 2015;29:459-525.
3.
National Institute for Health and Clinical Excellence: Depression in Adults: Recognition and Management [Internet]. 2009. http://www.nice.org.uk/guidance/cg90 (accessed Jan 4, 2016).
4.
Piek E, van der Meer K, Nolen WA: Guideline recommendations for long-term treatment of depression with antidepressants in primary care - a critical review. Eur J Gen Pract 2010;16:106-112.
5.
Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J, Kasper S: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008;9:248-312.
6.
GIP/College voor Zorgverzekeringen: Aantal Gebruikers 2006-2010 voor ATC-Subgroep N06: Psychoanaleptica Raming voor de Totale Zvw-Populatie. 2016. www.gipdatabank.nl (accessed October 26, 2016).
7.
De Graaf R, Ten Have M, Van Gool C, Van Dorsselaer S: Prevalentie van psychische aandoeningen en trends van 1996 to 2009: resultaten van NEMESIS-2. Tijdschr Psychiatr 2012;54:27-38.
8.
Noordam R, Aarts N, Verhamme KM, Sturkenboom MC, Stricker BH, Visser LE: Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study. Eur J Clin Pharmacol 2015;71:369-375.
9.
Olfson M, Marcus SC: National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848-856.
10.
Moore M, Yueng HM, Dunn N, Mullee MA, Maskell J, Kendrick T: Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 2009;339:b3999.
11.
Vektis: TherapietrouwMonitor. 2015. http://www.therapietrouwmonitor.nl/cijfers/depressie-0 (accessed Sep 9, 2015).
12.
Mojtabai R, Olfson M: National trends in long-term use of antidepressant medications: results from the US National Health and Nutrition Examination Survey. J Clin Psychiatry 2014;75:169-177.
13.
Bosman RC, Huijbregts KM, Verhaak PF, Ruhé HG, Van Marwijk HW, van Balkom AJ, Batelaan NM: Long-term antidepressant use: a qualitative study on perspectives of patients and GPs. Br J Gen Pract 2016;66:e708-e719.
14.
Batelaan NM, Bosman RC, Muntingh A, Scholten W, Huijbregts KM; van Balkom AJLM: Is it wise to discontinue antidepressants in anxiety disorders? A meta-analysis of relapse prevention trials. BMJ 2017;358:j3927.
15.
Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-661.
16.
Leydon GM, Rodgers L, Kendrick T: A qualitative study of patient views on discontinuing long-term selective serotonin reuptake inhibitors. Fam Pract 2007;24:570-575.
17.
Fava GA: Rational use of antidepressant drugs. Psychother Psychosom 2014;83:197-204.
18.
Ashton AK, Jamerson BD, L Weinstein W, Wagoner C: Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp 2005;66:96-106.
19.
19 Cohen A, Gilman SE, Houck PR, Szanto K, Reynolds CF 3rd: Socioeconomic status and anxiety as predictors of antidepressant treatment response and suicidal ideation in older adults. Soc Psychiatry Psychiatr Epidemiol 2009;44:272-277.
20.
20 Cloos J, Bocquet V, Rolland-Portal I, Koch P, Chouinard G: Hypnotics and triazolobenzodiazepines - best predictors of high-dose benzodiazepine use: results from the Luxembourg National Health Insurance Registry. Psychother Psychosom 2015;84:273-283.
21.
Netherlands College of General Practitioners (NHG): NHG standaard Angst. 2012. https://www.nhg.org/standaarden/volledig/nhg-standaard-angst#idm114768 (accessed Jan 21, 2014).
22.
Netherlands College of General Practitioners (NHG): Standaard Depressie. 2012. https://www.nhg.org/standaarden/samenvatting/depressie#idp42371872 (accessed April 5, 2014).
23.
De Waal MW, Arnold IA, Eekhof JA, Van Hemert AM: Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 2004;184:470-476.
24.
Bentzen N (ed): WONCA international glossary for general/family practice. Fam Pract 1995;12:267.
25.
Johnson CF, Macdonald HJ, Atkinson P, Buchanan AI, Downes N, Dougall N: Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. Br J Gen Pract 2012;62:773-779.
26.
Vektis; Instituut voor Verantwoord Medicjngebruik: Volume long-term users of antidepressant medication. https://www.volksgezondheidenzorg.info/onderwerp/eerstelijnszorg/regionaal-internationaal/huisartsenzorg#node-voorschrijfgedrag-therapiekeuze-tweepositiepostcodegebied (accessed February 14, 2017).
27.
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015;84:72-81.
28.
Netherlands College of General Practitioners (NHG): NHG Standaard Pijn. 2016. https://www.nhg.org/standaarden/volledig/nhg-standaard-pijn (accessed Aug 16, 2016).
29.
Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015;84:63-71.
30.
Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016;85:270-288.
31.
Gardarsdottir H, Egberts TC, Stolker JJ, Heerdink ER: Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias. Am J Epidemiol 2009;170:280-285.
32.
Cosci F, Guidi J, Balon R, Fava GA: Clinical methodology matters in epidemiology: not all benzodiazepines are the same. Psychother Psychosom 2015;84:262-264.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.